<DOC>
	<DOCNO>NCT01747577</DOCNO>
	<brief_summary>The purpose study demonstrate superiority solifenacin succinate ( treatment ) placebo ( control ) base change baseline mean number urgency episodes per 24 hour 2 week .</brief_summary>
	<brief_title>Post Marketing Study Evaluate Efficacy Safety Solifenacin Patients With OAB ( Overactive Bladder ) After TURP ( Trans-urethral Resection Prostate ) PVP ( Photoselective Vaporization Prostate )</brief_title>
	<detailed_description>The BPH ( benign prostate hyperplasia ) patient OAB ( overactive bladder ) TURP ( trans-urethral resection prostate ) PVP ( photoselective vaporization prostate ) participate study . The subject randomize 1:1 solifenacin succinate group placebo treatment group . The subject shall take investigational product night sleep four week complete void diary . At Week-2 Week-4 treatment , subject ask complete follow activity : physical exam , vital sign test , IPSS , OABSS , post-void residual ( PVR ) test , uroflowmetry , ask answer BSW , ( Benefit , Satisfaction Willingness Continue Questions ) questionnaire .</detailed_description>
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Urinary Bladder , Overactive</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Solifenacin Succinate</mesh_term>
	<criteria>Screening Patients willing able accurately complete void diary , IPSS , OABSS Patients diagnose BPH schedule receive TURP PVP Randomization ( TURP PVP ) Patients diagnose OAB investigator Patients underwent catheter removal 5Â±2 day beforehand average three urgency episode per 24 hrs average eight micturition per 24 hr row Visit 3 , record void diary Patients score 5 question 2 , 4 , 7 , storage symptom IPSS Patients score 4 question 3 5 OABSS Patients treat medication overactive bladder ( OAB ) symptoms 14 day randomization Screening Patients diagnosed prostate cancer bladder cancer present resolve malignant disease pelvic organ Patients neurological disease affect micturition cause neurogenic bladder disease multiple sclerosis , Parkinson 's disease , severe cerebral arteriosclerosis , dementia , stroke , myelitis Patients serious adverse event hypersensitive anticholinergic Patients severe gastrointestinal obstruction disease toxin megacolon , ulcerative colitis , intestinal atonia , paralytic ileus , gastric retention Patients diagnose severe myasthenia Patients diagnose narrowangle glaucoma Patients serious hepatic impairment ( child class C ) Patients treat CYP3A4 inhibitor ( e.g. , Ketoconazole ) Patients severe renal impairment undergoing hemodialysis Patients diabetic neuropathy Patients significant urinogenital disease UTI , interstitial cystitis , urothelial tumor , bladder stone , urinary retention Patients rare hereditary problem galactose intolerance , Lapp lactase deficiency glucosegalactose malabsorption Patients another medical psychiatric condition make inappropriate participate study opinion investigator Patients participate clinical trial within 30 day screen visit Randomization Patients diagnose clinically significant bladder outlet obstruction investigator Patients whose PVR great 100 mL Patients diagnosed prostate cancer bladder cancer present resolve malignant disease pelvic organ Patients neurological disease affect micturition cause neurogenic bladder disease multiple sclerosis , Parkinson 's disease , severe cerebral arteriosclerosis , dementia , stroke , myelitis Patients serious adverse event hypersensitive anticholinergic Patients severe gastrointestinal obstruction disease toxin megacolon , ulcerative colitis , intestinal atonia , paralytic ileus , gastric retention Patients diagnose severe myasthenia Patients diagnose narrowangle glaucoma Patients serious hepatic impairment ( child class C ) Patients treat CYP3A4 inhibitor ( e.g. , Ketoconazole ) Patients severe renal impairment undergoing hemodialysis Patients experience severe side effect operation Patients diabetic neuropathy Patients significant urinogenital disease UTI , interstitial cystitis , urothelial tumor , bladder stone , urinary retention Patients rare hereditary problem galactose intolerance , Lapp lactase deficiency glucosegalactose malabsorption Patients another medical psychiatric condition make inappropriate participate study opinion investigator Patients participate clinical trial within 30 day screen visit</criteria>
	<gender>Male</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Muscarine antagonist</keyword>
	<keyword>Prostatectomy</keyword>
	<keyword>Uroflowmetry</keyword>
</DOC>